In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
Articles
The consequences of greater net price transparency for innovative medicines in Europe
December 15, 2020
Key contacts
Additional contributors
-
Kirsty Ross-Stewart
Consulting Associate
Upcoming events
Asembia’s AXS26 Summit
CRA is a proud supporter of the conference where attendees span the full spectrum of the pharmacy and healthcare ecosystem, bringing together key...
GAR Live: Life Sciences
CRA is a proud sponsor of the first-ever GAR Live: Life Sciences, evolving from the much-loved Technology Disputes event to reflect the growing complexity and...